Phathom Pharmaceuticals(PHAT)
FLORHAM PARK, NJ
PharmaceuticalFocus: Novel treatments for gastrointestinal diseases and disorders
Phathom Pharmaceuticals is a life sciences company focused on Novel treatments for gastrointestinal diseases and disorders.
GastroenterologyNeurology
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
0
Products & Portfolio (4)
Pipeline & Clinical Trials
Vonoprazan
Erosive EsophagitisClinical Trials (1)
NCT06660342A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
N/AVonoprazan
Gastroesophageal RefluxClinical Trials (1)
NCT05343364A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Phase 1Vonoprazan
Healthy ParticipantsClinical Trials (1)
NCT04729101Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants
Phase 1Vonoprazan
Erosive EsophagitisClinical Trials (1)
NCT06391177A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
Phase 1Vonoprazan
Gastroesophageal Reflux DiseaseClinical Trials (1)
NCT06106022A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
Phase 1Vonoprazan
Healthy ParticipantsClinical Trials (1)
NCT04558216Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
Phase 1Vonoprazan
Healthy VolunteersClinical Trials (1)
NCT05366738A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
Phase 1Vonoprazan
Healthy VolunteersClinical Trials (1)
NCT04545944Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
Phase 1Vonoprazan ODT-1 or ODT-2 without Water
Healthy VolunteersClinical Trials (1)
NCT06831344A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
Phase 1Phase 2
Clinical Trials (1)
NCT04799158A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Phase 2Vonoprazan
Eosinophilic EsophagitisClinical Trials (1)
NCT06851559A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
Phase 2Vonoprazan
Helicobacter Pylori InfectionClinical Trials (1)
NCT04167670Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
Phase 3Vonoprazan
Erosive EsophagitisClinical Trials (1)
NCT04124926Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
Phase 3Phase 3
Clinical Trials (1)
NCT05195528A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Phase 3PYTEST® 14C-Urea Capsule Breath Test
H. Pylori InfectionClinical Trials (1)
NCT07224048Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
Phase 4PYTEST® 14C-Urea Breath Test
H Pylori InfectionClinical Trials (1)
NCT07224035Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
Phase 4Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 4 approved products, 16 clinical trials
SEC Filings: 2 available
Portfolio Health
Growth2 (50%)
Peak2 (50%)
4 total products
Financials (FY2025)
Revenue
$55M8001%
R&D Spend
$34M(62%)32%
Net Income
-$334MCash
$297M